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The serrated pathway to colorectal tumor formation involves oncogenic mutations in the BRAF gene, which are
sufficient for initiation of hyperplastic growth but not for tumor progression. A previous analysis of colorectal
tumors revealed that overexpression of splice variant Rac1b occurs in around 80% of tumors with mutant BRAF
and both events proved to cooperate in tumor cell survival. Here, we provide evidence for increased expression of
Rac1b in patients with inflamed human colonic mucosa as well as following experimentally induced colitis in mice.
The increase of Rac1b in the mouse model was specifically prevented by the nonsteroidal anti-inflammatory drug
ibuprofen, which also inhibited Rac1b expression in cultured HT29 colorectal tumor cells through a cyclooxy-
genase inhibition–independent mechanism. Accordingly, the presence of ibuprofen led to a reduction of HT29 cell
survival in vitro and inhibited Rac1b-dependent tumor growth of HT29 xenografts. Together, our results suggest that
stromal cues, namely, inflammation, can trigger changes in Rac1b expression in the colon and identify ibuprofen as
a highly specific and efficient inhibitor of Rac1b overexpression in colorectal tumors. Our data suggest that the use
of ibuprofen may be beneficial in the treatment of patients with serrated colorectal tumors or with inflammatory
colon syndromes.
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Colorectal cancer (CRC) represents one of the leading causes of cancer
mortality in the Western world. The majority of cases are sporadic
tumors that present an adenoma-carcinoma sequence involving somatic
mutations in the adenomatous polyposis coli (APC) tumor suppressor
gene and in the oncogene KRAS [1]. In addition, about 10% to 15% of
cases are characterized by a high level of DNA microsatellite instability
as a result of somatic inactivation of a DNA mismatch repair gene.
These tumors mainly occur in the proximal colon segment and carry
a global CpG island hypermethylation phenotype (eventually including
the mismatch repair gene hMLH1) and oncogenic mutations in the
BRAF gene [2]. They follow a different neoplastic pathway that is
independent of KRAS and has been designated as the serrated polyp
pathway [3]. Genotyping of microdissected polyps has confirmed thatmutations in KRAS and BRAF are alternative early, tumor-initiating
events and that serrated polyps harbor BRAF mutations with a DNA
methylation phenotype [4–7].
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dominantly in melanoma, thyroid, and colorectal tumors. Although the
mutation activates the protein’s kinase activity and stimulates mitogen-
activated protein (MAP) kinases, BRAF-V600E alone has less onco-
genic potential than mutant KRAS in cell transformation assays [8].
We recently described that about 80% of BRAF-V600E–positive colo-
rectal tumors also overexpress Rac1b [9], a highly activated splice vari-
ant of the signaling GTPase Rac1. Rac1b lacks down-regulation by
Rho-GDI, exists predominantly in the GTP-bound active conforma-
tion, and promotes cell cycle progression and cell survival through
activation of the transcription factor nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κB) [10–12]. Importantly, colorectal
tumor cells expressing BRAF-V600E and Rac1b were highly sensitive
to combined inhibition of both events, leading to 80% cell death [9].
Based on the findings that BRAF-V600E and hyperactive Rac1b func-
tionally cooperate in tumor cells, a genetic pathway was proposed for
a subtype of colorectal tumors [9,13] that are initiated by a BRAF-
V600E mutation but later require overexpression of hyperactive Rac1b
to allow further tumor progression. It remains to be established, how-
ever, how the overexpression of Rac1b is triggered in tumor cells.
Tumor cells are known to interact with the stromal microenviron-
ment. For instance, tumor cells produce cytokines to which stromal
cells respond with the secretion of proteases that remodel the extra-
cellular matrix, of pro-angiogenic factors that attract blood vessels, and
of mitogenic factors that feedback on tumor cell survival. Vice versa,
cytokines released by the tumor microenvironment are now known
to further promote tumor cell growth at various stages of tumor devel-
opment [14,15]. In addition, stimulation of the NF-κB pathway is
simultaneously promoting an inflammatory response and a pro-survival
signal for epithelial cells [16,17]. Interestingly, colon tumors with
microsatellite instability or BRAF mutation are characterized by abun-
dant lymphocytic infiltration. Besides inflammation caused by infec-
tious or environmental agents, chronic inflammatory states in organs or
tissues have also been identified as a risk factor for cancer development
and promoted the prophylactic administration of anti-inflammatory
drugs to patients [18–20].
Here, we describe an increase inRac1b expression in inflamed colonic
as well as following experimental induction of colitis in laboratory mice.
We further identified the anti-inflammatory drug ibuprofen as a specific
inhibitor of both the increase in Rac1b expression and the survival of
corresponding Rac1b overexpressing tumor cells in vivo.
Materials and Methods
Human Tissue Samples
All research programs involving the use of human tissue were
approved and supported by the INSERM (French National Institute
for Health and Medical Research) Ethics Committee and these tissues
are considered as surgical waste in accordance with French ethical laws
(L.1211-3–L.1211-9).
Human colonic mucosa specimens were obtained from patients
who had undergone surgery for colonic inflammation (two patients
with Crohn’s disease and four patients with diverticulitis). Four of
the six inflamed samples were matched with the corresponding distant
macroscopically healthy mucosa (the two patients with Crohn’s dis-
ease and the two patients with diverticulitis). Two additional samples
of control mucosa were obtained from colonic resections for colon
cancer and dissected from at least 10 cm from the tumors. Tissue sam-
ples were snap frozen in liquid nitrogen and stored at −80°C until use.Cell Culture, Transfection, and Selection Conditions
HT29 cells were maintained in RPMI and SW480 in Dulbecco’s
modified Eagle’s medium, both supplemented with 10% (vol/vol)
fetal calf serum (all reagents from Gibco Invitrogen Corporation,
Barcelona, Spain). The normal colonocyte cell line NCM460 [21]
was received by a licensing agreement with INCELL Corporation
(San Antonio, TX). The cells were routinely propagated under stan-
dard conditions in M3:10 medium (INCELL) containing 10% fetal
calf serum.
For biochemical assays, cells were seeded in 24- or 96-well plates at
2 × 105 or 3 × 104 cells/well and treated with either vehicle (DMSO)
or the indicated concentrations of the various DMSO-diluted anti-
inflammatory compounds (all from Sigma-Aldrich, Madrid, Spain).
Cells were then analyzed at the indicated time points by various
methodologies (see below).
To generate cell lines stably expressing ectopic green fluorescent
protein (GFP) or GFP-Rac1b wild type (wt) [10], HT29 cells
were transfected with either vector using LIPOFECTAMINE 2000
(Invitrogen), according to the manufacturer’s instructions, and selected
for 4 weeks with G418 (Sigma-Aldrich) at 500 μg/ml. Brighter clones
were then collected, pooled and cultured for 2 additional weeks before
use in biochemical assays or mouse xenografts and maintained at
250 μg/ml G418 while in culture.
SiRNA and Inducible BRAF-V600E Expression
SiRNA-mediated depletion of endogenous Rac1b and BRAF-
V600E expression in HT29 cells was performed as previously described
[9]. For inducible expression of BRAF-V600E in NCM460, the com-
plete BRAF coding sequence was amplified by polymerase chain
reaction (PCR) from a pEGFP-BRAF-V600E construct [9] and sub-
cloned using SacI and SalI restriction sites into the pPTuner vector of
the ProteoTuner Shield System N (Clontech, Mountain View, CA).
This vector generates a fusion protein with the FKBP (L106P) de-
stabilization domain that causes the rapid constitutive degradation of
the fusion protein until the addition of Shield1 to the culture medium.
Shield1 is a membrane permeable stabilizing ligand that binds to
the destabilization domain tag, “shielding” the fusion protein from
proteasomal degradation and thus allowing its rapid accumulation.
Reverse Transcription–PCR and Real-Time PCR
Colonic mucosa and xenograft-derived tumors were disrupted
using a Polytron apparatus and RNA was isolated using NucleoSpin
RNA II Kit (Macherey-Nagel, Hoerdt, France). RNA from cell line
cultures was extracted with the RNAeasy Kit (Qiagen, Hilden,
Germany). One microgram of total RNA was then reverse transcribed
using random primers (Invitrogen) and Ready-to-Go You-Prime Beads
(GE Healthcare, Buckinghamshire, United Kingdom).
Real-time relative quantification was performed as described [9]
with minor alterations, namely, all mouse samples were analyzed
against a cDNA sample prepared from total RNA from NIH 3T3 cells,
and the reverse primer from the “total Rac1 detector” pair was changed
to 5′-GATGAT AGGAGTATTGGGACAGT to eliminate mouse/
human mismatches.
Immunofluorescence Microscopy
Cells grown on coverslips were fixed with 4% (vol/vol) formaldehyde
(Merck, Darmstadt, Germany) in phosphate-buffered saline and permea-
bilized with 0.2% (vol/vol) Triton X-100 (Sigma) in phosphate-buffered
saline. Cells were then stained with 4′,6-diamidino-2-phenylindole
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confocal microscope and processed with Adobe Photoshop software.
Sodium Dodecyl Sulfate–Polyacrylamide Gel Electrophoresis
and Western Blot Analysis
Samples were prepared and detected as described [9]. The anti-
bodies used in this study were rabbit anti-GFP ab290 from Abcam
(Cambridge,UnitedKingdom), polyclonal rabbit anti-Rac1b (Millipore,
Billerica, MA, #09-271), and mouse anti–β-tubulin clone Tub2.1 from
Sigma-Aldrich (as a loading control). For densitometric analysis, film
exposures from at least three independent experiments were digitalized
and analyzed using ImageJ software National Institutes of Health (NIH).
Cell Viability and Prostaglandin E2 Assays
HT29 cells seeded in 96-well plates were treated for the indicated
periods with the given nonsteroidal anti-inflammatory drug (NSAID)
concentrations. Cell viability was evaluated using the CellTiter-Glo
ATP-based luminescence assay (Promega, Madison, WI) and plotted
as percent of DMSO-treated cells at the same time points. The amount
of prostaglandin E2 (PGE2) released by the cells to the culture medium
was determined using the DetectX PGE2 Chemiluminescent Enzyme
Immunoassay (Arbor Assays, Ann Arbor, MI) according to the manu-
facturer’s protocol. Luminescent signals were recorded with a Lucy 2
microtiter plate luminometer (Anthos, Krefeld, Germany). All results
were confirmed by at least three independent experiments.
Mice Dextran Sulfate Sodium Treatment and
Tumor Xenografts
All experiments on mice were performed in accordance with institu-
tional and national guidelines and regulations, and ethics approval was ob-
tained from the INSERMEthics Committee.Male C57BL/6 and nude
mice were purchased from Charles River Laboratories (Lille, France).
To induce colitis, C57BL/6 mice (10–12 weeks old) received
dextran sulfate sodium (DSS; 36–50 kDa; MP Biomedicals Europe,
Illkirch, France) dissolved in sterile tap water (3% wt/vol) or ibuprofen
(1 mg/ml) or a combination of the two compounds. DSS treatment
was carried out for 5 days, followed by two recovery days, whereas
ibuprofen was administered throughout the 7 days. Control groups re-
ceived sterile tap water. Body weight was monitored daily in all groups.
Mice were killed by cervical dislocation. The cecum was removed and
the remainder of the colon was divided into proximal and distal halves.
For tumorigenicity assay in nude mice, exponentially growing
parental, GFP, or GFP-Rac1b wt stably expressing HT29 cells
were harvested and resuspended to a concentration of 2 × 107/ml.
Cells (2 × 106) were inoculated in the right flank of mice (day 0).
Animals were then fed with aspirin or ibuprofen in drinking water at
doses adjusted for bodymass from regular human posologies (1mg/ml).
Tumor development was followed weekly by caliper measurement
along two orthogonal axes, length (L) and width (W ). The volume
(V ) of tumor was calculated by the equation for ellipsoid (V = L ×
W 2 × π/6). After euthanasia on day 28, tumors were dissected from
neighboring connective tissues and weighed. Then, they were divided
into three parts and snap frozen in liquid nitrogen and stored at −80°C
until further processing.
Statistical Analysis
All results are expressed as means ± SEM. Differences between
controls and the multiple treatments applied to mice or cultured cellswere evaluated by one-way analysis of variance test, followed by
unpaired two-tailed Student’s t tests when significant results were
obtained. When relevant, direct statistical comparisons between
two groups were made using unpaired two-tailed t tests. The level
of significance was set at P ≤ .05.Results
BRAF-V600E Mutation and Rac1b Overexpression Constitute
Two Independent Events in Colorectal Tumorigenesis
We previously found that most colorectal tumors carrying the
BRAF-V600E mutation also show Rac1b overexpression and that
Rac1b was required to sustain survival and tumorigenicity of colo-
rectal tumor cells [9]. To understand how the overexpression of
Rac1b was triggered in colorectal tumors, we asked whether mutant
BRAF, which has been widely considered as the tumor-initiating
event, was sufficient to cause Rac1b overexpression. For this, we first
used HT29 tumor cells, which were previously identified as a model
for the BRAF-V600E/Rac1b tumor type, and depleted expression of
the mutant BRAF-V600E allele by RNA interference. We observed
that under these conditions the expression levels of endogenous Rac1b
remained unaffected (Figure 1A ). Next, we overexpressed oncogenic
BRAF-V600E in nontransformed human colonocyte NCM460 [21]
that we found to express endogenous Rac1b at levels comparable to
normal colonmucosa (Figure 1B); however, no evidence for an increase
in Rac1b expression was observed (Figure 1C ). Together, these
data strongly suggest that the presence of mutant BRAF alone was
not sufficient to induce overexpression of Rac1b and that BRAF
mutation and Rac1b overexpression constitute two independent events
in colorectal tumorigenesis.Pro-inflammatory Cues Are Associated with Rac1b
Overexpression In Vivo
Another well-known factor promoting tumor cell progression is
the surrounding tumor cell microenvironment [14–16]. Inflamma-
tion, for example, constitutes a persistent challenge of the mucosa
tissue and has been associated with increased risk for CRC [22,23].
This prompted us to determine whether patients with inflammatory
diseases of the colon would reveal altered Rac1b expression in the
affected mucosa cells. RNA samples from surgery specimens of
inflamed and control colonic mucosa from six affected individuals
were analyzed by quantitative reverse transcription–PCR (qPCR) and
showed a mean increase of 1.6-fold in Rac1b transcript (Figure 2A).
This is comparable to the roughly two-fold increase in the alter-
native splicing of Rac1b that we observed in the colorectal cell line
HT29 [9] and which was sufficient to yield a high level of active
Rac1b protein due to the hyperactivation properties of this variant
[10,24,25].
To further investigate the hypothesis that pro-inflammatory cues
may promote Rac1b expression, a mouse model for experimentally
induced colitis was employed. Mice were fed with the polymer
DSS in drinking water for 5 days. After 2 days of recovery with water
(acute colitis), animals were sacrificed. Expression of Rac1b in proximal
and distal colon segments was analyzed by qPCR and revealed a more
than two-fold up-regulation of the alternative transcript Rac1b (Fig-
ure 2B). These in vivo experiments strongly supported the possibility
that the inflammatory process is involved in Rac1b overexpression.
Figure 1. Thepresence of oncogenic BRAF is insufficient to increase
Rac1b expression. (A) HT29 colon cancer cells, expressing one
endogenous mutated BRAF-V600E allele and Rac1b, were trans-
fected with either BRAF-V600E–specific, Rac1b-specific, or control
siRNA oligonucleotides, as described [9]. Following 48 hours, the re-
sulting expression levels of BRAF and Rac1b proteins were analyzed
byWestern blot. Note that specific reduction in the accumulation of
the oncogenic BRAF variant had no effect on Rac1b levels. (B)
NCM460 normal colonocytes present endogenous Rac1b mRNA
levels comparable to that observed in five healthy human colonic
mucosa (M) samples. (C) Inducible overexpression of BRAF-V600E
in NCM460 cells did not induce any changes in Rac1b protein levels.
Figure 2. An inflammatory microenvironment enhanced Rac1b
expression in colonic cells. (A) The relative accumulation of Rac1b
transcripts was evaluated by qPCR in RNA samples isolated from
six surgical samples of inflamed colonic mucosa and in six sam-
ples of healthy colonic tissue. (B) Induction of Rac1b transcript
accumulation during acute experimental colitis. Mice (n = 20)
were treated with the polymer DSS to induce acute colonic inflam-
mation, and Rac1b mRNA levels were determined by qPCR in
both the proximal (A) and distal (B) colons of the DSS-treated and
control mice.
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CRC Cells
NSAIDs are widely used to treat inflammatory processes and their
regular administration has been reported to delay sporadic colorectal
tumor growth and to cause regression of polyps [18–20]. Because
most of the anti-tumorigenic effects of NSAIDs were derived from
in vitro studies using cancer cell lines, including HT29 [26–28], we
tested whether a panel of NSAIDs and other compounds, previously
described to have an ameliorative effect in CRC [26,27,29,30], would
also affect Rac1b expression levels in these cells. Following 48 hours of
treatment with a broad range of drug concentrations [26,29–32], only
ibuprofen and indomethacin appeared to decrease Rac1b expression
in a dose-dependent manner, whereas eight of the nine remaining
drugs, including aspirin, had either no effect or lacked dose depen-
dency (see Figure 3A ). Unexpectedly, the drug piroxicam actually
increased expression of the Rac1b transcript. Experiments were then
repeated for four selected drugs using a time course and the con-centration range found in the plasma of patients on continuous thera-
peutic regimens [29,31–33]. The results confirmed that at usual
therapeutic concentrations only ibuprofen treatment caused a sig-
nificant decrease in Rac1b expression in these cells (Figure 2B ),
reaching levels close to those found in healthy colon mucosa [9].
Aspirin had no effect on Rac1b expression and indomethacin failed
to produce an effect as robust as ibuprofen. Notably, piroxicam repro-
ducibly induced an increase in Rac1b (Figure 3B ).Ibuprofen Decreases the Viability of HT29 Cells through a
COX-Independent Mechanism Requiring Rac1b
Down-Regulation
Rac1b signaling has been previously described to sustain colorectal
tumor cell survival [9,12]. We thus asked whether the changes in
Rac1b expression were reflected by changes in HT29 cell viability.
Indeed, cell treatment with ibuprofen, but not aspirin, significantly
decreased the viability of HT29 cells by 50% (Figure 4A). We fur-
ther reasoned that if ibuprofen treatment was reducing HT29 cell
viability through Rac1b down-regulation, treatment should have no
effect on SW480 cells that do not express this Rac1 variant. Indeed, at
these low but therapeutically relevant concentrations, the viability of
SW480 cells was unaffected. Only after 96 hours of treatment with
Figure 3. Effect of NSAIDs on Rac1b mRNA levels in HT29 cells. (A) Cells were incubated for 48 hours with a panel of NSAIDs at the
indicated concentrations and lysed for RNA extraction in order to analyze the respective Rac1bmRNA accumulation by qPCR. Abbreviations
are given as follows: ASA = aspirin, IBU = ibuprofen, FBP = flurbiprofen, NPX = naproxen, SS = sulindac sulfide, IDM = indomethacin,
KLT = Ketorolac, PIR = piroxicam, PBZ = phenylbutazone, NS = NS398, CUR = curcumin. (B) HT29 cells were incubated with clinically
relevant concentrations described in patient plasma of either indomethacin, piroxicam, aspirin, or ibuprofen for up to 96 hours before
Rac1b mRNA levels were determined by qPCR. Rac1b levels found in normal colon mucosa are shown as a dotted line.
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tion in cell viability was observed, compatible with a general cytotoxic
effect at later time points. To test the effect of ibuprofen on normal
colon cells, these experiments were also performed in nontransformed
human colonocyte NCM460. Neither ibuprofen nor aspirin treat-
ment had any significant effect on NCM460 viability (Figure 4A ).
These results suggested that ibuprofen specifically acts on Rac1b over-
expressing cells.
The inhibition of cyclooxygenases (COXs), particularly of COX-2,
which is frequently overexpressed by tumor cells [34], has been cor-
related with the anti-tumorigenic activity of NSAIDs. Moreover,
HT29 cells have been reported to express higher levels of COX-2 than
SW480 cells [35], and ibuprofen is a more potent COX-2 inhibitor
than aspirin [36]. We therefore asked whether the observed effect ofibuprofen on HT29 cell viability correlated with COX-2 activity.
COX-2 catalyzes the conversion of arachidonic acid to a number of
prostaglandins including pro-tumorigenic PGE2 [34], which was
therefore chosen to monitor COX-2 activity in HT29 cells treated
with either ibuprofen or aspirin. We found that both drugs signifi-
cantly inhibited PGE2 production just after 24 hours of treatment
(Figure 4B ). Thus, although the treatment conditions with either
aspirin or ibuprofen yielded equivalent degrees of COX inhibition,
only ibuprofen affected Rac1b expression levels and cell viability.
These data suggested that the effect of ibuprofen on Rac1b is unrelated
to COX activity.
To examine whether the effect of ibuprofen on HT29 cell viability
is directly dependent on Rac1b, we generated HT29 cells that stably
express either GFP alone (control) or an ectopic GFP-Rac1b cDNA.
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ibuprofen had on expression of endogenous Rac1b, which is known to
be regulated at the alternative splicing level. As shown in Figure 4C ,
this ectopic Rac1b protein clearly rescued the inhibitory effect of ibu-Figure 4. Effect of aspirin and ibuprofen on the viability of cultured
treatments was determined for HT29 cells (Rac1b overexpression), S
colonocyte NCM460 (low-level Rac1b expression). Note that only ibu
overexpressing HT29 cells. (B) Comparison of the production of PGE
of COX inhibition. (C) Survival of HT29 cells in the presence of ibuprof
vector. (D) Western blot analysis of endogenous and ectopic GFP-tag
ibuprofen or untreated. A fluorescence microscopy image of a stab
localization of Rac1b, as previously described [10], is also shown.profen on cell viability, although in these cells ibuprofen still led to the
reduction in endogenous Rac1b protein described above (Figure 4D).
Together, these results strongly indicated that ibuprofen inhibits HT29
cell viability by directly interfering with Rac1b overexpression.colonic cells. (A) The effect on cell survival of the indicated drug
W480 cells (no endogenous Rac1b expression), and normal human
profen affected cell viability and this occurred selectively in Rac1b
2 in HT29 cells treated with either ibuprofen or aspirin, as an index
en following transfection with a control or a GFP-Rac1b expression
ged Rac1b in the total protein extracts from HT29 cells treated with
le GFP-Rac1b expressing clone demonstrating plasma membrane
Figure 5. Effect of anti-inflammatory drugs on HT29 xenograft growth in nude mice. HT29 cancer cells (2 × 106) were injected in flank of
nude mice (n = 18) to generate xenograft tumors. Animals were divided into three groups and treated with either ibuprofen or aspirin
(1 mg/ml) in drinking water, whereas the control group received water. (A) Representatives images of tumor xenograft at the time of
sacrifice, and (B) graphic growth curve of the tumor volume. (C) The weight of the excised tumors was obtained and presented as
means ± SEM. (D) Rac1b mRNA levels were determined by qPCR analysis under the indicated treatments. (E) HT29 GFP or HT29
GFP-Rac1b cells (2 × 106) were injected as subcutaneous xenografts into nude mice (n = 18), which were treated with ibuprofen or
left untreated. The weight comparison and (F) representative images of the xenograft-derived tumors recovered after 28 days are shown.
Note that ectopic Rac1b expression prevented ibuprofen from inhibiting tumor growth.
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Encouraged by these observations, we next determined whether
ibuprofen would also inhibit the growth of these BRAFV600E/Rac1b
overexpression–positive tumor cells under in vivo conditions. Xeno-
grafts ofHT29 cells were produced by subcutaneous injection into nude
mice and animals fedwith aspirin or ibuprofen in drinking water at doses
adjusted for body mass from regular human posologies (1 mg/ml).
Tumor growth was followed for 4 weeks (Figure 5, A and B), animals
were then killed, the tumors resected and weighed, and RNA was
extracted for qPCR analysis of Rac1b (Figure 5, C and D). Ibuprofen
treatment clearly restrained tumor growth (P < .001), whereas aspirin
produced no significant effect (P = .929). This correlated with a cor-
responding and significant decrease in Rac1b expression levels in the
ibuprofen-treated tumors (Figure 5D). To further support the conclusion
of a crucial role of Rac1b in this process, xenografts of the HT29 cells
stably expressing GFP-Rac1b or GFP alone (control) were produced
and the ibuprofen treatments were repeated. As shown in Figure 5, Eand F , a clear reduction in the growth-inhibitory effect of ibuprofen
was observed with the GFP Rac1b xenografts, whereas the GFP control
cells responded to ibuprofen with a growth arrest equivalent to that
observed for parental HT29 cells. Together, these data show that ibupro-
fen, besides its general anti-inflammatory effect, targets the expression of
alternative spliced Rac1b and this action is the underlying mechanism
for the observed growth inhibition of xenograft-derived tumors.Ibuprofen Prevents the Acute Inflammation-Induced
Rac1b Overexpression
As described above, we observed an increase in Rac1b levels in
patients with colon inflammatory disorders and following acute colitis
induction in mice. Because ibuprofen was able to inhibit Rac1b expres-
sion and tumor growth in HT29 xenografts, we investigated whether
ibuprofen was also able to counteract the acute inflammation-induced
increase in Rac1b expression. Mice were treated with DSS as described
above either in the presence or absence of ibuprofen. As expected for
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loss of DSS-treated mice (Figure 6A ). In addition, the treatment
strongly inhibited Rac1b elevation in both the proximal and distal
mouse colons (Figure 6, B and C , respectively).Figure 6. Ibuprofen attenuates the weight loss and the increase in
Rac1b expression during acute colitis in mice. Mice (n = 6) were
treated with the polymer DSS to induce acute colitis in the absence
or presence of ibuprofen (1 mg/ml) in the drinking water. The weight
curves of treated mice during the 7-day period (A) are shown. Rac1b
mRNA levels were determined by qPCR in both the proximal (B)
and distal (C) colons isolated from sacrificed animals.Discussion
Rac1b is an alternative splicing variant of the small GTPase Rac1
found overexpressed in colon [37], breast [38], and lung tumors
[39–41]. In colon, Rac1b overexpression preferentially occurred in
a specific subgroup of tumors that are characterized by mutation
in the BRAF oncogene [9]. This is of interest because recent trans-
genic mouse models revealed that expression of mutant BRAF in either
skin [42], lung [43], or colon [44] drives an initial proliferative response
but then leads to oncogene-induced senescence. The observed over-
expression of Rac1b in BRAF-mutated colon tumors thus represents
one candidate mechanism involved in oncogene-induced senescence
escape. Consistently, we previously described that the survival of rep-
resentative tumor cells such as HT29 depends on both BRAF-V600E
and Rac1b overexpression [9]. It remains, however, unclear how Rac1b
expression is induced, in particular because the mere presence of
mutant BRAF was insufficient to alter Rac1b expression levels (see
Figure 1). Whereas in a mammary carcinoma cell model the activity
of extracellular matrix metalloproteinase 3 was able to induce Rac1b
[45], it is unknown whether this also applies to other cell types such
as colon.
One major novel finding of this work is that colon inflammation can
trigger increased Rac1b expression. This was observed during experi-
mentally induced acute colitis in mice but also in surgical samples from
patients with inflammatory diseases of the colon. These data suggest
that stroma-derived signals can induce changes in the generation or
stability of the alternative spliced Rac1b transcript in colonocytes.
The last decade has revealed numerous examples of cytokines pro-
duced by stromal fibroblasts or immune cells, including tumor necrosis
factor-alpha (TNFα), interleukins-1 (IL-1), IL-6, and IL-23, which
stimulate tumor cell progression in a paracrine manner [15,17]. In addi-
tion, tumor cells produce cytokines to which stromal cells respond with
the secretion of proteases, angiogenesis, or release of mitogenic factors
that feedback on tumor cell survival. These latter mitogenic signals fre-
quently activate NF-κB in the tumor cell [16,17], a pathway also acti-
vated downstream of Rac1b signaling [10,11]. Thus, stroma-derived
signals may favor tumorigenesis of the mentioned subgroup of colorectal
tumors through the switch in Rac1b expression in cancer cells, the
subsequent NF-κB stimulation leading to increased cell survival. The
molecular identity of such signals is currently being investigated, but
preliminary data indicate that the overexpression of IL-8, a previously
described marker of chronic colonic inflammation [46] and CRC pro-
gression [47], may be involved (data not shown). In this sense, our data
indicate that the emergence of Rac1b overexpression may not be the
consequence of a second mutational event in a BRAF mutant cell but
rather a response of the initiated tumor cell to stroma-derived signals.
A second major finding of this work is that ibuprofen has a specific
inhibitory effect on Rac1b overexpression.We found in culturedHT29
cells that Rac1b expression and, consequently, Rac1b-mediated tumor
cell survival were significantly and selectively reduced upon incubation
with ibuprofen but not with other commonly used NSAIDs, namely,
aspirin. In contrast, the survival of SW480 cells that do not express
Rac1b was not significantly affected under the same conditions
(Figure 4A). Although inflammation is a complex process, these in vitro
studies indicate that ibuprofen exerts a direct and specific action on
Rac1b-positive CRC cells that is not activated by other NSAIDS such
as aspirin. Consequently, ibuprofen was able to specifically inhibit the
Rac1b-dependent growth of HT29 tumor xenografts. Moreover, this
inhibitory effect of ibuprofen was rescued by constitutive overexpres-
sion of wild-type Rac1b in derivatives of HT29 cells. The HT29 cell
110 Ibuprofen Counteracts Rac1b Overexpression Matos et al. Neoplasia Vol. 15, No. 1, 2013line is a model for the specific subgroup of colorectal tumors character-
ized by mutation in the BRAF oncogene and Rac1b overexpression [9].
In these cells, aspirin had no effect on xenograft growth, although it has
been clearly shown to inhibit the growth of other colon tumor cells,
which mostly harbor other oncogenic mutations.
Ibuprofen shares with other NSAIDs such as aspirin the ability to
inhibit the activity of COX-1 and COX-2 and thus to reduce the
generation of pro-inflammatory stimuli. Consistently, we found that
under the experimental conditions employed ibuprofen as well as
aspirin inhibited COX activity; however, only ibuprofen affected
Rac1b levels, demonstrating that its mechanism of action is COX-
independent. Because we used therapeutically relevant ibuprofen
concentrations that are comparable to those found in patient plasma,
the observed reduction in Rac1b is not an unspecific off-target effect
but rather an additional mode of action of ibuprofen. Indeed, several
NSAIDs were described to have COX-independent mechanisms of
action [28,48,49], but how ibuprofen inhibits Rac1b expression
remains to be determined. Rac1b expression is most likely regulated
at the alternative splicing level and so far no data were reported on
any effect of ibuprofen on this process. In one case, ibuprofen was
found to increase mRNA stability mediated through the p38 MAPK
pathway [50]. Our results are in agreement with previous reports
showing that ibuprofen treatment of colorectal tumor cells markedly
decreased their viability, both in vitro and in vivo [51,52].
In this sense, the presented experimental data suggest potential
clinical implications for our findings. First, the group of patients with
proximal colorectal tumors of the serrated polyp type that usually
contains oncogenic BRAF mutations is likely to benefit from adjuvant
and preventive therapy with ibuprofen. This can be clearly deduced
from the inhibitory effect on the HT29 xenograft. Second, feedingmice
with ibuprofen reduced the experimental inflammation-mediated
increase in Rac1b in their colon, suggesting a beneficial effect of ibu-
profen in colon cancer chemoprevention, namely, by inhibiting the pro-
gression of BRAF-mutated tumor-initiated cells through Rac1b
overexpression. It is important to note that previous analyses of inflam-
matory disease–associated colon tumors found BRAF mutation fre-
quencies comparable to sporadic colon cancer, including the high
prevalence in tumors with microsatellite instability [53,54].
Moreover, our findings indicate that the beneficial effect of
NSAIDs in CRCmay not rely solely on an anti-inflammatory response.
Although aspirin has been successfully used to inhibit colon cancer
growth on the one hand, it likely provides less prevention against the
growth of serrated tumors than ibuprofen. However, the administra-
tion of some NSAIDs, such as piroxicam, may even promote this type
of Rac1b-related tumor development. Thus, our data imply that the
efficacy of NSAID treatment may show discrepancies depending on
the subtype of the initiated tumor that is present.References
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